Table 2.
Characteristics of Patients With Serum Samples Used in This Comparative Study
| Sample Type (Year Collected) | Samples (Unique Patients), No. | Sex, Male/Total, No. | Age, Range (Median) y | Days After Symptom Onset, Range (Median) | Hospital Admission, No. |
|---|---|---|---|---|---|
| Prepandemic presumptive negative (2016-2019) | 74 (74) | ||||
| Samples with demographics | 31 (31) | 17/31 | 12-79 (46) | ||
| Cross-reactivity panel (2020) | 63 (63) | ||||
| Seasonal coronavirus | 13 (13) | 6/13 | 2-83 (55) | ||
| HKU1 | 7 | ||||
| OC43 | 2 | ||||
| NL63 | 2 | ||||
| 229E | 2 | ||||
| Hepatitis B | 10 (10) | 5/10 | 22-72 (48) | ||
| Hepatitis C | 10 (10) | 710 | 20-74 (62) | ||
| Autoimmune | 30 (30) | 4/30 | 12-71 (40) | ||
| ANA | 10 | ||||
| ENA | 7 | ||||
| Anti-dsDNA | 17 | ||||
| RF | 6 | ||||
| Increased IgG | 5 | ||||
| M-protein | 1 | ||||
| Anti-EBV | 1 | ||||
| Anti-HSV 1 and 2 | 1 | ||||
| Clinical RT-PCR negative (2020) | 53 (53) | 13/53 | 16-64 (40) | 0-52a (4) | |
| Symptom onset >14 d | 25 (25) | 6/25 | 17-61 (41) | 15-52 (32) | |
| Symptom onset <14 d | 28 (28) | 7/28 | 16-64 (38) | 0-4a (0) | |
| Clinical RT-PCR positive (2020) | 131 (68) | 29/68 | 23-65 (49) | 5-59 (20) | 35 |
| Retrospective serology | 36 (35) | 10/35 | 23-65 (38) | 18-59b (41) | 2 |
| Prospective medical care | 95 (33) | 19/33 | 27-85 (63) | 5-29 (14) | 33 |
ANA, anti–nuclear antibody by immunofluorescence; dsDNA, double-stranded DNA; EBV, Epstein-Barr virus; ENA, anti–nuclear antibody by multiplex extractable nuclear antigen; HSV, herpes simplex virus; RF, rheumatoid factor; RT-PCR, reverse transcription polymerase chain reaction.
aOne patient without symptoms.
bRange excluding first sample on day 0 of a patient with two samples.